VISTAGEN THERAPEUTICS INC (VTGN)

US92840H4002 - Common Stock

3.34  +0.02 (+0.75%)

After market: 3.4 +0.06 (+1.8%)

Fundamental Rating

3

Taking everything into account, VTGN scores 3 out of 10 in our fundamental rating. VTGN was compared to 564 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for VTGN as it has an excellent financial health rating, but there are worries on the profitability. VTGN is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year VTGN has reported negative net income.
VTGN had a negative operating cash flow in the past year.
VTGN had negative earnings in each of the past 5 years.
VTGN had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -38.60%, VTGN is in line with its industry, outperforming 58.53% of the companies in the same industry.
The Return On Equity of VTGN (-42.56%) is better than 71.45% of its industry peers.
Industry RankSector Rank
ROA -38.6%
ROE -42.56%
ROIC N/A
ROA(3y)-123.28%
ROA(5y)-157.78%
ROE(3y)-196.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

VTGN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

7

2. Health

2.1 Basic Checks

VTGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VTGN has been increased compared to 1 year ago.
The number of shares outstanding for VTGN has been increased compared to 5 years ago.
There is no outstanding debt for VTGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 0.29, we must say that VTGN is in the distress zone and has some risk of bankruptcy.
VTGN has a better Altman-Z score (0.29) than 63.73% of its industry peers.
VTGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.29
ROIC/WACCN/A
WACC10.61%

2.3 Liquidity

VTGN has a Current Ratio of 13.29. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
VTGN's Current ratio of 13.29 is amongst the best of the industry. VTGN outperforms 87.25% of its industry peers.
VTGN has a Quick Ratio of 13.29. This indicates that VTGN is financially healthy and has no problem in meeting its short term obligations.
VTGN has a better Quick ratio (13.29) than 87.25% of its industry peers.
Industry RankSector Rank
Current Ratio 13.29
Quick Ratio 13.29

More info and screens

5

3. Growth

3.1 Past

VTGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 72.76%, which is quite impressive.
The Revenue has been growing slightly by 6.79% in the past year.
Measured over the past years, VTGN shows a decrease in Revenue. The Revenue has been decreasing by -0.80% on average per year.
EPS 1Y (TTM)72.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)6.79%
Revenue growth 3Y-0.8%
Revenue growth 5YN/A
Sales Q2Q%-34.1%

3.2 Future

The Earnings Per Share is expected to grow by 22.60% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 200.60% on average over the next years. This is a very strong growth
EPS Next Y-14.71%
EPS Next 2Y-8.91%
EPS Next 3Y-8.67%
EPS Next 5Y22.6%
Revenue Next Year-39.5%
Revenue Next 2Y-45.51%
Revenue Next 3Y63.35%
Revenue Next 5Y200.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VTGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as VTGN's earnings are expected to decrease with -8.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.91%
EPS Next 3Y-8.67%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VTGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VISTAGEN THERAPEUTICS INC

NASDAQ:VTGN (1/3/2025, 8:09:33 PM)

After market: 3.4 +0.06 (+1.8%)

3.34

+0.02 (+0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-11 2025-02-11/amc
Inst Owners59.18%
Inst Owner Change-6.59%
Ins Owners0.26%
Ins Owner Change0%
Market Cap92.99M
Analysts88
Price Target12.24 (266.47%)
Short Float %1.48%
Short Ratio1.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.85%
Min EPS beat(2)-5.58%
Max EPS beat(2)15.27%
EPS beat(4)3
Avg EPS beat(4)17.69%
Min EPS beat(4)-5.58%
Max EPS beat(4)32.39%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-46.11%
Min Revenue beat(2)-72.55%
Max Revenue beat(2)-19.67%
Revenue beat(4)0
Avg Revenue beat(4)-30.72%
Min Revenue beat(4)-72.55%
Max Revenue beat(4)-4.74%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.11%
PT rev (3m)-7.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)12.07%
EPS NY rev (1m)0%
EPS NY rev (3m)-6.08%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-6.86%
Revenue NY rev (3m)-8.32%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 106.18
P/FCF N/A
P/OCF N/A
P/B 1
P/tB 1
EV/EBITDA N/A
EPS(TTM)-1.24
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.2
OCFYN/A
SpS0.03
BVpS3.34
TBVpS3.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.6%
ROE -42.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-123.28%
ROA(5y)-157.78%
ROE(3y)-196.88%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.84%
Cap/Sales 18.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.29
Quick Ratio 13.29
Altman-Z 0.29
F-Score3
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)114.3%
Cap/Depr(5y)115.25%
Cap/Sales(3y)38.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y-14.71%
EPS Next 2Y-8.91%
EPS Next 3Y-8.67%
EPS Next 5Y22.6%
Revenue 1Y (TTM)6.79%
Revenue growth 3Y-0.8%
Revenue growth 5YN/A
Sales Q2Q%-34.1%
Revenue Next Year-39.5%
Revenue Next 2Y-45.51%
Revenue Next 3Y63.35%
Revenue Next 5Y200.6%
EBIT growth 1Y-27.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.14%
OCF growth 3YN/A
OCF growth 5YN/A